Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jesse Shaw

Orthopaedic Surgery Pembroke Pines, FL Doctor of Osteopathy

NPI 1396865788 CMS profile 199252

17779 Sw 2Nd St, Pembroke Pines, FL 33029

Open in the dashboard

General payments

$17,806

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Shaw of Pembroke Pines, FL is reported in the CMS Open Payments database as having received $17,806 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,653 14
2024 General $9,922 12
2023 General $618 8
2022 General $513 8
2021 General $673 11
2020 General $861 16
2019 General $566 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Shaw
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jesse Shaw were reported at $4,653. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jesse Shaw Orthopaedic Surgery median Middle half National median
2019 $566 $644 $140–$2,844 $163
2020 $861 $312 $75–$1,860 $114
2021 $673 $520 $117–$2,495 $132
2022 $513 $598 $128–$2,731 $149
2023 $618 $461 $128–$2,264 $160
2024 $9,922 $497 $134–$2,475 $164
2025 $4,653 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NovoSource, LLC $13,725 2 payments
  2. Zimmer Biomet Holdings, Inc. $1,469 16 payments
  3. Smith+Nephew, Inc. $602 13 payments
  4. Embody, Inc. $427 4 payments
  5. DePuy Synthes Sales Inc. $393 10 payments
  6. Stryker Corporation $306 5 payments
  7. Abanza Inc. $143 1 payment
  8. Electronic Waveform Lab, Inc. $118 7 payments
  9. Integra LifeSciences Corporation $86 1 payment
  10. OssDsign Incorporated $80 1 payment
  11. Other $458 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,725 2 payments
  2. Food and Beverage $4,081 80 payments
Products named General payments · program years 2019–2025
  1. REGENETEN Shoulder $230 4 payments
  2. LENS 4K $195 2 payments
  3. Tapestry $185 2 payments
  4. Connected Health-MyMobility $144 1 payment
  5. WasherCap Fixation System 10mm $143 1 payment
  6. PSI Anatomical Shoulder $143 1 payment
  7. Comprehensive Shoulder System $142 1 payment
  8. Tricera Handpiece $139 1 payment
  9. AccuFill $125 1 payment
  10. Quatro Link $121 1 payment
  11. Other $2,992 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

301

Median for Orthopedic Surgery: 203

Drug cost

$88,144

Median for Orthopedic Surgery: $1,433

Branded share of claims

54.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zilretta Triamcinolone Acetonide Brand 85 $86,874
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 67 $443
Diclofenac Sodium Generic 40 $380
Methylprednisolone Generic 23 $153
Methocarbamol Generic 35 $126
Gabapentin Generic 12 $55
Ibuprofen Generic 14 $49
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $41
Meloxicam Generic 14 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$45,932

Of which drugs: $3,223

Medicare patients

108

Average age 72

Services billed

2,205

75 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 45%
Depression 37%
Chronic kidney disease 31%
Ischemic heart disease 28%
COPD 27%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 13 28 $2,779
Injection, methylprednisolone acetate, 1 mg J1010 Office 31 1,722 $173
Injection, methylprednisolone acetate, 40 mg J1030 Office 16 18 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record